United States · Biotechnology startup

Sana Biotechnology

Sana Biotechnology is a developer of engineered cells intended to be used as medicine for patients.

Funding reportedLast round: Post ipo equity

BiotechnologySeattle, United States

What company datasets say Sana Biotechnology raised

Funding, as reported

Reported in all$865Min dollars
Rounds4
Last roundPost ipo equity
Last round dateFeb 2024
Investors listed13
SEC Form D$867M sold, 2 filings, last Jun 2020

Founders and team

From Sana Biotechnology's own website and the SEC filings it signed: 7 on the team.

  • Aaron GrossmanExecutive Vice President, Chief Legal Officer
  • Debra WisdomVice President, Head of People
  • Rob RosielloDirector
  • Hans J. BishopChairman
  • James J. MacDonaldExecutive Officeri
  • Nathan D. HardyExecutive Officeri
  • Steven D. HarrExecutive Officer, Directori

On the board, as filediDonald J. PayanDouglas J. ColeGeoffrey J. von MaltzahnMary Agnes J. WilderotterPatrick J. YangRichard J. MulliganRobert J. NelsenStephen J. Knight

On 4 portfolio pages

Investors who name them

Each firm lists Sana Biotechnology on its own website. That is the firm's claim, a weaker thing than a round we watched, but a named source.

Biotechnology in United States

Startups like it

Is this your company?

Add your raise, your deck and your story, and put Sana Biotechnology in front of investors. Or tell us what we have wrong.

List your startupSend a correction